Australia's Proteomics International Laboratories rises on positive cancer study results

Proteomics International Laboratories

23/09/2024 03:58

** Shares of Proteomics International Labs  PIQ.AX  rise as
much as 8.4% to A$0.71
    ** The medical technology co says its PromarkerEso blood
test for esophageal adenocarcinoma shows 94% accuracy in
clinical validation study
    ** Co says esophageal adenocarcinoma, a cancer arising in
the food pipe, is among the leading cause of cancer-related
deaths, with a 5-year survival rate of 20%, due to late
diagnosis
    ** Says improved surveillance of at-risk patients using
PromarkerEso could enable earlier diagnosis and significantly
improve health outcomes
    ** Stock has fallen 26.8% this year, as of last close

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com))